Clinical trial NCT01704703: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
Official title: Open Label Phase II Study of FOLFIRI + Panitumumab Using Ultra-selection Technology With Next Generation High Sensitivity Genotyping of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Stage IV Colorectal Cancer
Keywords: colorectal cancer
FOLFIRI
Panitumumab
KRAS, PIK3Ca,BRAF and NRAS genes
highly sensitive techniques
Lead sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Sponsor class: OTHER
First posted: 2012-10-11
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and NRAS genes detected with highly sensitive techniques.


Eligibility criteria: Inclusion Criteria:

1. Competent to understand, sign and date an IEC-approved informed consent form.
2. Men or women 18 years of age or older at the time the written informed consent is obtained.
3. Histologically confirmed metastatic adenocarcinoma of the colon or rectum Wild-Type RAS (No mutation) with at least 1 measurable metastatic lesion following RECIST criteria v 1.1 and initially irresectable (non suitable for radical surgery at the inclusion time).
4. Obtention of DNA from tumor tissue blocks sent to central lab (ICO) that is amenable for highly sensitive techniques
5. Previous irinotecan based chemotherapy +/- bevacizumab for metastatic CCR during at least 6 weeks.
6. Irinotecan based chemotherapy does not need to be the most recent chemotherapy administrated. There are no restrictions on numbers of treatments lines before study inclusion.
7. Disease progression during irinotecan treatment or within 6 months after irinotecan treatment.
8. Karnofsky status ≥ 70% .
9. Adequate bone marrow, hepatic, renal and metabolic functions,

   1. Adequate bone marrow function: neutrophils ≥ 1.5x109/ L; platelets ≥ 100x109/L; hemoglobin ≥ 9g/dL.
   2. Hepatic functions as follows: total bilirubin count ≤ 1.5 x ULN; ALAT and ASAT ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastasis).
   3. Renal function: creatinine clearance \> 50 ml/min (according Cockcroft y Gault formulae)
   4. Metabolic functions: magnesium ≥ lower limit of normal (LIN)
10. Life expectancy ≥ 3 months.

Exclusion Criteria:

1. Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of the skin or pre-invasive cervical cancer.
2. Unresolved toxicities from prior systemic therapy and/or radiotherapy that, in the opinion of the investigator, does not qualify the patient for inclusion.
3. Documented or suspected central nervous system metastases.
4. Any previous antitumoral treatment (chemotherapy, hormonal therapy, radiation treatment, surgery, immunotherapy, biologic therapy) ≤ 28 days before study inclusion.
5. Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia.
6. Prior anti-EGFr antibody therapy (eg, Cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, Erlotinib). Subjects who discontinue their first dose of anti-EGFR therapy (Cetuximab) because of an infusion reaction may participate in this clinical trial.
7. Paraffin-embedded tissue or unstained tumor slides from primary or metastatic tumor not available or quality ADN not available for biomarker determination by highly sensitive techniques.
8. History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis.
9. Treatment for systemic infection within 14 days before study inclusion.
10. Acute or sub-acute intestinal occlusion and /or active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day).
11. History of Gilbert's syndrome or dihydropyrimidine deficiency.
12. History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results.
13. Known positive test for human immunodeficiency virus infection, hepatitis C virus, and chronic active hepatitis B infection.
14. Subject allergic to the ingredients of the study medication or to Staphylococcus protein A.
15. Any co-morbid disease that would increase risk of toxicity.
16. Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures.
17. Subject who is pregnant or breast feeding.
18. Surgery (excluding diagnostic biopsy or central venous catheter placement) ≤ 28 days prior study inclusion.
19. Woman or man of childbearing potential not consenting to use adequate contraceptive precautions.
20. Subject unwilling or unable to comply with study requirements.
21. Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Primary outcomes:
measure: Objective response rate (TRO)
timeFrame: 4 years
Secondary outcomes:
measure: disease control rate (TCE)
timeFrame: 4 years
measure: duration of response (DR)
timeFrame: 4 years
measure: time to response(THR)
timeFrame: 4 years
measure: time to progression (THP)
timeFrame: 4 years
measure: time to treatment failure (THF)
timeFrame: 4 years
measure: duration of stable disease (DEE)
timeFrame: 4 years
measure: Progression free survival (SLP)
timeFrame: 4 years
measure: Overall survival (SG)
timeFrame: 4 years
measure: Adverse events
timeFrame: 4 years
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Spanish Cooperative Group for Digestive Tumour Therapy
Study officials:
affiliation: Institut Català d´Oncologia (ICO) L'Hospitalet
name: Ramón Salazar, MD, PhD
role: STUDY_CHAIR
affiliation: Institut Català d´Oncologia (ICO) L'Hospitalet
name: Gabriel Capella
role: STUDY_CHAIR
References:
citation: Santos C, Azuara D, Vieitez JM, Paez D, Falco E, Elez E, Lopez-Lopez C, Valladares M, Robles-Diaz L, Garcia-Alfonso P, Buges C, Duran G, Salud A, Navarro V, Capella G, Aranda E, Salazar R. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082.